Latelines for June 16, 2003.
Wegovy Shows Early Reduction in Major Adverse Cardiovascular Events
Semaglutide resulted in a significant reduction in the risk of MACE within the first 3 months of treatment compared to placebo.
Demystifying PBMs, Their Role in the Drug Supply Chain
President of 3 Axis Advisors and CEO of 46brooklyn Research joins Drug Topics to discuss nuances surrounding pharmacy benefit managers and the way they are perceived in the public eye.
Pharmacists Must Stay Knowledgeable on Evolving IRA Provisions | NCPDP 2025
Greg Miller, RPh, discussed the past, present, and future of the Inflation Reduction Act and key insights pharmacists should understand in order to keep up with the legislation.
Scripted for Her: Helping Patients Choose Contraceptive Methods
In this episode of the podcast, Natalie DiPietro Mager, PharmD, PhD, sits down with Jasmine Cutler, PharmD, CPh.
Tirzepatide Shows Superior Weight Loss Over Semaglutide in Phase 3 Trial
Tirzepatide (Zepbound) demonstrated superiority compared to semaglutide (Wegovy) across the primary end point and 5 key secondary end points.
President Trump Signs Executive Order Significantly Decreasing US Drug Prices
The order is set to make patients’ prescription costs similar to other nations with the lowest-priced drugs in the world.
